Catalyst Pharmaceuticals

Catalyst is developing amifampridine phosphate for the treatment of LEMS, a rare neuromuscular, autoimmune disorder frequently associated with small cell lung cancer. Catalyst also believes that amifampridine phosphate has the potential to treat other neuromuscular disorders such as congenital myasthenic syndromes and some cases of myasthenia gravis that are refractory to currently approved therapies.
Company Growth (employees)
Type
Public
HQ
Coral Gables, US
Founded
2002
Size (employees)
18 (est)
Catalyst Pharmaceuticals was founded in 2002 and is headquartered in Coral Gables, US

Catalyst Pharmaceuticals Office Locations

Catalyst Pharmaceuticals has an office in Coral Gables
Coral Gables, US (HQ)
1250 355 Alhambra Cir

Catalyst Pharmaceuticals Financials and Metrics

Catalyst Pharmaceuticals Financials

Catalyst Pharmaceuticals's revenue was reported to be $0 in FY, 2016
USD

Net income (Q2, 2017)

(3.9 m)

EBIT (Q2, 2017)

(4.2 m)

Market capitalization (13-Nov-2017)

248.5 m

Cash (30-Jun-2017)

8.6 m
Catalyst Pharmaceuticals's current market capitalization is $248.5 m.
USDFY, 2014FY, 2015FY, 2016

R&D expense

10.1 m11.8 m11.4 m

General and administrative expense

4.5 m8.6 m7.9 m

Operating expense total

14.6 m20.4 m19.3 m

EBIT

(14.6 m)(20.4 m)(19.3 m)
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

R&D expense

2.6 m3 m3.5 m2.5 m2.5 m2.8 m2.5 m

General and administrative expense

2.3 m2 m2.7 m2.3 m1.4 m1.9 m1.7 m

Operating expense total

4.9 m5 m6.2 m4.8 m3.9 m4.7 m4.2 m

EBIT

(4.9 m)(5 m)(6.2 m)(4.8 m)(3.9 m)(4.7 m)(4.2 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

2.2 m9.1 m28.2 m13.9 m

Inventories

4.6 m1.5 m1 m

Current Assets

25.3 m43.8 m59.9 m41.5 m

PP&E

40.6 k71.4 k191.5 k244.2 k
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

41.3 m37.2 m32.8 m22.2 m18.7 m17.6 m10 m8.6 m

Current Assets

76 m68.3 m64.4 m53.5 m48.7 m45.1 m37.5 m35.8 m

PP&E

71.1 k63.3 k197.6 k178.4 k258.5 k249 k231.2 k218.3 k

Total Assets

76 m68.3 m64.6 m53.7 m48.9 m45.3 m37.7 m36 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(12.2 m)(15.5 m)(20.2 m)(18.1 m)

Depreciation and Amortization

22.5 k26.6 k34.5 k43.4 k

Accounts Payable

(514.9 k)963.4 k(20.1 k)(861 k)

Cash From Operating Activities

(9.9 m)(12.9 m)(18 m)(18 m)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(10 m)(14.4 m)(5.4 m)(10 m)(13.9 m)(5 m)(8.8 m)

Depreciation and Amortization

17.1 k28.4 k13.2 k22 k31.4 k13 k25.9 k

Accounts Payable

1.5 m932.1 k1.2 m524.8 k(497.9 k)(997.2 k)(542.7 k)(1.1 m)(738.8 k)(15.2 k)(240.8 k)

Cash From Operating Activities

(8 m)(13.4 m)(5.9 m)(10.3 m)(13.6 m)(3.9 m)(7.1 m)
Y, 2017

Financial Leverage

1.1 x
Show all financial metrics

Catalyst Pharmaceuticals Market Value History

Catalyst Pharmaceuticals's Web-traffic and Trends

Catalyst Pharmaceuticals Online and Social Media Presence

Catalyst Pharmaceuticals Company Life and Culture

You may also be interested in